Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...
Stocktwits on MSN
Genmab stock slips after discontinuing further development of cancer drug developed with BioNTech
The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...
New clinical evidence indicates that a widely used supplement may alter gut microbes involved in vitamin D biology and ...
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit Looks Back at Pancreatic Cancer in 2025: A Year of Progress, ...
One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs ...
15don MSN
Cracking the code of a hidden cancer receptor: How scientists found the first true Frizzled blocker
Researchers at Karolinska Institutet have identified small molecules capable of influencing a hard-to-target receptor family linked to cancer development. The findings have been published in Nature ...
With enrollment completed and encouraging immune response and safety data observed in the Phase 1 trial, Anixa plans to advance the vaccine into a Phase 2 clinical trial and has assumed full ...
Starton Holdings filed for an initial public offering, as it works to develop a treatment for blood cancers. The clinical-stage biotechnology company plans to offer about 6.7 million shares priced at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results